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The microtubule-targeting agents (MTAs) are a very successful class of cancer drugs with therapeutic beneﬁts in both hematopoi-
etic and solid tumors. However, resistance to these drugs is a signiﬁcant problem. Current MTAs bind to microtubules, and/or to
their constituent tubulin heterodimers, and aﬀect microtubule polymerization and dynamics. The PPARγ inhibitor T0070907 can
reduce tubulin levels in colorectal cancer cell lines and suppress tumor growth in a murine xenograft model. T0070907 does not
altermicrotubulepolymerizationinvitro,anddoesnotappeartoworkbytriggeringmodulationoftubulinRNAlevelssubsequent
to decreased polymerization. This observation suggests the possible development of antimicrotubule drugs that work by a novel
mechanism, and implies the presence of cancer therapeutic targets that have not yet been exploited. This review summarizes what
is known about PPARγ inhibitors and cancer cell death, with emphasis on the tubulin phenotype and PPAR-dependence, and
identiﬁes potential mechanisms of action.
Copyright © 2008 Katherine L. Schaefer. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The peroxisome proliferator-activated receptors (PPARs)
are ligand-activated nuclear hormone receptors that act
as transcriptional modulators. They have important roles
in control of metabolism, inﬂammation, and cell growth
and diﬀerentiation. There are three PPAR isoforms (γ,
β/δ,a n dα) with overlapping but distinct tissue expression
patterns and cellular functions [1]. Much evidence suggests
that PPARγ activity can modulate tumor development,
implicating PPARγ as animportant therapeutic cancertarget
[2].
PPARγ (NR1C3) is able to both activate and repress
transcription, depending on the promoter that is involved
[3]. In the classical pathway, PPARγ binds to promoters
containing PPAR-response elements (PPREs) in combina-
tion with its heterodimer partner, the retinoid X receptor.
Activator ligand binding to PPARγ causes a structural shift
thatincreasesitsabilitytorecruittranscriptionalcoactivators
while decreasing its basal ability to bind to corepressors [4].
PPARγ also exhibits transrepressive functions at promoters
lacking a PPRE [5], by binding in a ligand-dependent
manner to transcription factors, cofactors, or repressor com-
plexes. In these cases, PPARγ binding inhibits transcription,
eitherby binding/sequestering the transcription factorsorby
preventing clearance of repressor complexes. In at least one
case of transrepression, the speciﬁc PPARγ conformational
shift required is diﬀerent from that required for cofactor
r e c r u i t m e n ta tP P R E s[ 6]. It is worth noting here that
since PPARγ has basal ligand-independent repression [5]
and activation functions [3], the eﬀects of PPARγ inhibitor
binding and PPARγ knockdown may not be the same.
PPARγ can be activated pharmacologically by thiazoli-
denedione (TZD) compounds, including the antidiabetic
drugs pioglitazone and rosiglitazone. There are multiple
studies showing that high doses of TZDs can inhibit tumor
growth in cell lines and mouse models. Clinical trials are
currently underway testing TZDs as chemopreventive and
therapeutic agents in human cancers [11]. While TZDs
act to stimulate PPARγ activity, they also have multiple
PPARγ-independent eﬀects, and the speciﬁc role of PPARγ
activation itself in the therapeutic eﬀects of TZDs is still an
active area of research. These topics are reviewed, from the
point of view of cancer therapeutic eﬀects, in several recent
reviews [11–18] and elsewhere in this special issue of PPAR
research.2 PPAR Research
Table 1: Eﬀects of PPARγ inhibitors on PPARγ,P P A R α,a n dP P A R δ activity IC50 (nM) for ability to compete with a PPAR agonist.
Binding Direct binding assay Activation of GAL4 chimera References
PPARγ PPARα PPARδ PPARγ PPARα PPARδ
GW9662 Irreversible 4 188 471 [7]
5 39 1200 8 630(1) 4100 [8]
T0070907 Irreversible 1 850 1800 1μM completely inhibits γ with no eﬀect on α or δ(2) [9]
BADGE Reversible 100000 100μM ∼70% inhibits γ with little or no eﬀect on α or δ(2) [10]
(1)GW9662 is also a partial activator of PPARα with an EC50 of 22nM [8], leading to the apparently higher concentrations of GW9662 required to inhibit
PPARα than would be predicted by the direct binding assay.
(2) Dose curves were not performed, but the indicated concentrations suppressed the GAL4 chimera as indicated.
SeveralstudiesindicatethatPPARγ inhibitorcompounds
are also able to reduce tumor growth in preclinical models
[9, 19–29]. As with the TZDs, the precise role of the loss of
PPARγ a c t i v i t yi nc e l ld e a t hi sa na c t i v er e s e a r c ha r e a ,a n d
may depend on the speciﬁc cell type. Our recent observation
that PPARγ inhibitors can cause rapid dissolution of the
microtubule network in colon cancer cells [26] suggests that
these compounds might act as microtubule-targeting agents
(MTAs), similar to the taxanes or Vinca alkaloids that are
in current clinical use. However, unlike MTAs [30], they
markedly reduce concentrations of α and β tubulin proteins
long before a commitment to apoptosis, and do not strongly
aﬀect microtubule polymerization in vitro. This review
will focus on the strong possibility that PPARγ inhibitor
compounds represent a new class of tubulin-targeting agents
[31].
2. BINDING ACTIVITY OF PPARγ ACTIVATORS
AND INHIBITORS
The PPARγ ligand-binding pocket can accommodate a
variety of lipophilic molecules [32]. Many cellular fatty acids
activate PPARγ, including oxidized low-density lipoproteins,
unsaturated fatty acids, 15-hydroxyeicosatetraenoic acid,
and 9- and 13-hydroxyoctadecadienoic acids. In addition,
the putative endogenous ligand prostaglandin 15-deoxy
delta-(12,14)-prostaglandin J2, as well as the TZD anti-
diabetic drugs [32] ,a r ea b l et oa c t i v a t eP P A R γ. The anti-
inﬂammatory drug 5-aminosalicylic acid binds to PPARγ
at therapeutic doses [33], as do other nonsteroidal anti-
inﬂammatory drugs [34], although both classes of medi-
cations are lower aﬃnity ligands than the TZDs. Ligand
binding introduces PPARγ conformational shifts that favor
recruitment of transcriptional coactivators over corepressors
orthatpromotespeciﬁcposttranslationalmodiﬁcations,and
it is these changes that dictate the transcriptional activity
of PPARγ. All of these ligands also have multiple eﬀects
that are independent of PPARγ, especially at high doses
[13, 32]. In addition, the identity and regulation of true
endogenous ligands is poorly understood at the present
time.
PPARγ also binds to a number of compounds that
are able to inhibit TZD-mediated PPARγ activation (see
[35] for chemical structures). These include halofenate [36]
and its enantiomer metaglidasen [37], SR-202 [38], G3335
and its derivatives [35, 39], T0070907 [9], GW9662 [8],
and bisphenol-A-diglycidyl-ether (BADGE) [10]. PPARγ
inhibitors probably suppress PPARγ activation both by
preventing binding by endogenous or exogenously added
ligands, and by inducing speciﬁc conformational shifts that
actively promote repression [9]. However, the details of these
conformational changes are less well understood than for the
activators. Of the known PPARγ inhibitors, only T0070907,
GW9662, and BADGE have been tested for their eﬀects on
cancer cell death; all three can cause cell death in multiple
cancer cell types at high-micromolar concentrations.
Interpreting the eﬀects of the cancer-targeting PPARγ
inhibitors is diﬃcult, since they can act as activators or
inhibitors, depending on the concentration used. They also
bind to multiple members of the PPAR family (and quite
possibly to other molecules) at high doses. At low micromo-
lar doses, T0070907 and GW9662 also bind to and inhibit
PPARα and PPARδ (Table 1). In addition, at low nanomolar
doses, GW9662 is a partial activator of PPARα. While the
ability of T0070907 to activate PPARα has not been checked,
it is possible that this compound may behave in the same
manner. Similarly, there are reports that BADGE can act
as a PPARγ activator at lower doses (10–30μM) than those
needed for inhibitory eﬀects [28, 40].
3. STANDARD MICROTUBULE
TARGETING AGENTS ACT BY INTERFERING
WITH MICROTUBULE DYNAMICS
Microtubules are long, tube-shaped polymers, formed by
ordered arrays of α/β tubulin heterodimers (Figure 1), that
make up one of the major components of the cellular
cytoskeleton. Precise regulation of microtubule function
is essential for maintenance of cell shape and polarity,
migration, regulation of cell signaling cascades, intracellular
transport, and cell division [41]. Microtubule function is
governed by a variety of active changes in microtubule
structure collectively termed microtubule dynamics.M i c r o -
tubules normally alternate between phases of growth and
rapid shrinking (dynamic instability), and also move tubulin
heterodimers from one end of the polymer to the other
(treadmilling) [42]. These processes are regulated in the cell
by a host of microtubule-associated proteins with varied
functions[43–46].Bothdynamicinstabilityandtreadmilling
are required for mitosis, and are almost certainly necessary
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Figure 1: Microtubule formation depends both on chaperone-
mediated production and assembly of α/β heterodimers and on
microtubule-associated proteins. Production of α and β tubulin
proteins requires assistance from chaperone proteins. The chaper-
one prefoldin associates with nascent tubulin polypeptide chains
and delivers them to the CCT chaperone. CCT folds them into
stable forms, which are delivered to the tubulin cofactors A
and B [47]. CoA and CoB both transfer tubulin monomers to
the CoC/D/E complex, which assembles the monomers into α/β
heterodimers ready for introduction into microtubules. Tubulin
reservoirs are held by the microtubule-associated protein stathmin
(green box), which, depending on phosphorylation, binds to free
tubulin and also destabilizes microtubule polymers. A host of
micotubule-associated proteins (green circles) associate with the
microtubule and regulate addition and removal of heterodimers
from both ends of the microtubule; in some cases, they have
been shown to regulate tubulin levels. While MTA therapies like
the taxanes and Vinca alkaloids target the equilibrium between
α/β tubulin heterodimer and the microtubule polymer, PPARγ
inhibitors could be aﬀecting any of the chaperone proteins or one
of the microtubule-associated proteins that is involved in control of
tubulin levels.
Given the importance of rapid cell proliferation and
migration to tumor development, it is not surprising that
the microtubule-targeting agents (MTAs) are one of the
most successful classes of cancer therapeutics, with clinical
applications in hematological cancers and solid tumors of
the head/neck, breast, ovaries, testes, lung, gastric tissue, and
prostate [48]. MTAs are a chemically and structurally diverse
sets of small molecules that bind to microtubules, tubulin, or
both, and interfere with microtubule function [44]. Despite
this diversity, all known MTAs bind at or near to one of
three domains: the taxane domain, the Vinca domain, or
the colchicine domain. Historically, MTAs have been divided
into microtubule-stabilizing and microtubule-destabilizing
agents, based on their eﬀects at high doses on polymer
mass in in vitro polymerization assays. However, while the
classiﬁcation remains in use, and these eﬀects clearly occur
in vivo at high doses, it is becoming generally accepted that
MTAs at clinically relevant concentrations primarily act by
disrupting microtubule dynamics, rather than by aﬀecting
bulk polymerization [30, 49]. The microtubule-disrupting
eﬀect leads to cell cycle arrest. In addition, MTAs may also
cause apoptosis by mechanisms that ultimately prove to be at
leastpartiallyindependentoftheeﬀectonthemitoticspindle
[50, 51].
Discovery and development of new microtubule-binding
compounds is an area of active research. In contrast, less
eﬀort has been spent on considering whether reducing
tubulin levels directly, and thereby altering microtubule
function, could be used to impair cancer cells. Our recent
results, showing that PPARγ inhibitors reduce tubulin levels
in HT-29 colon cancer cells, before a commitment to
apoptosis [26], suggest that targeting tubulin itself may be
av i a b l es t r a t e g y .
4. PPARγ INHIBITORS CAUSE APOPTOSIS IN
MULTIPLE CANCER CELL TYPES AND
CAUSE RAPID LOSS OF TUBULIN PROTEINS
IN COLON CANCER CELLS
Experiments with many diﬀerent cancer cell lines show
that high doses of PPARγ inhibitors can cause cell death.
T0070907 and/or GW9662 exhibited antiproliferative eﬀects
in both hematopoietic cell lines from non-Hodgkin’s lym-
phoma and multiple myeloma [27] and epithelial cancer
cell lines, including carcinoma cell lines from renal [27],
breast [21, 22, 27], liver [23, 52], oral squamous [29],
esophageal [24], prostate [22], and colon tissue [22, 26].
IC50concentrationsforinhibitionofgrowthintheepithelial
lines ranged from 3–50μM for T0070907 and 10–50μM
for GW9662. While the reasons for this reduction in cell
number have not been explored in all cases, T0070907 and
GW9662 clearly caused apoptosis in several epithelial cell
lines. BADGE also exhibited cytotoxic eﬀects against colon
cancer cell lines [20, 22, 25, 31] and a T lymphoma cell line
[19, 20], at doses in the 100–200μMr a n g e .
In HT-29 colon cancer cells, treatment with 50μM
T0070907 led to dissolution of the microtubule network
w i t h i n1 2h o u r s[ 26]. At this timepoint, the eﬀects of
T0070907 were reversible. However, after longer exposure,
the cells became committed to caspase-dependent apoptosis.
Cells treated with T0070907 also assumed a rounded shape
that occurred prior to commitment to apoptosis, and that
was not aﬀected by caspase inhibitors. Similar eﬀects and
timing were seen with the PPARγ inhibitor GW9662 ([26]
and KLS, unpublished data).
Loss of the microtubule network is associated with the
microtubule-depolymerizing class of MTAs that includes
vinblastine, vincristine, vinorelbine, and nocodazole [30,
53]. Thus, it was especially striking that, unlike nocodazole,
T0070907 and GW9662 did not aﬀect microtubule poly-
merization in in vitro assays [26]. Instead, α and β tubulin
protein levels in the cells dropped rapidly after treatment
with these compounds, suggesting that the microtubule
network disappeared because tubulin protein levels were
below critical thresholds needed for polymerization. BADGE
also caused tubulin loss, although the timing of this loss
relative to commitment to apoptosis was not determined.
It is not currently known whether PPARγ inhibitors cause
loss of tubulin in other cell lines. While many of the other
experiments with inhibitors documented altered cytoskeletal4 PPAR Research
structure[23–25,29],itwasnotclearinthesepaperswhether
the altered shape was the result or the cause of apoptosis, and
tubulin levels were not measured directly.
5. IS TUBULIN LOSS REQUIRED FOR CELL DEATH
INDUCED BY T0070907 AND GW9662?
TheeﬀectsofT0070907andGW9662ontubulinarestriking,
especially as there have not been any reports of cancer cell-
targeting small molecules that aﬀect tubulin levels without
dramatic eﬀects on microtubule polymerization. However,
it is not clear that the ultimate cause of cell death is loss
of tubulin. These compounds may independently target a
combination of signaling pathways that ultimately trigger
the apoptotic response as well as modulating tubulin levels.
Given the fact that the PPARγ inhibitors also trigger loss
of γ and δ tubulin isoforms (KLS, unpublished data), it
will be diﬃcult to do genetic replacement experiments to
address this issue in the absence of other information about
the reasons for tubulin loss. Regardless of whether or not
microtubule disruption is the ﬁrst trigger for apoptosis,
the reduction in tubulin should serve as a barrier that is
impossible for the tumor cells to surmount. This eﬀect could
have profound advantages, in that simply modulating the
levelsofanti-apoptoticproteinsinresponsetochemotherapy
would not be suﬃc i e n tt oa l l o wt u m o re s c a p e .
Intriguingly, commitment to apoptosis in HT-29 cells
occurred at about the same time that tubulin levels dropped
below a threshold level for normal function observed in
yeast.After12hoursofT0070907treatment,whenthetumor
cells had lost ∼50% of their tubulin, the eﬀects of the
drug were still reversible. By the time, 50% of the cells had
committed to apoptosis (∼20h), the average tubulin level
w a sl e s st h a n1 0 %o fc o n t r o l( [ 26] and data not shown),
suggesting that apoptosis may be triggered by tubulin levels
below 50% of normal. These numbers parallel observations
in the yeast Saccharomyes cerevisiae, which was able to
tolerate a 50% reduction in either α or β tubulin, as long as
there were not excess unpaired β tubulin molecules [54, 55],
but which began to show defects in mitosis when levels
dropped to ∼20% of normal.
6. WHAT COULD BE CAUSING THE LOSS OF
TUBULIN INDUCED BY T0070907?
The reasons for T0070907-mediated tubulin loss remain
to be elucidated, and may well be the result of multiple
coordinatedchangestakingplaceinthecontextofalterations
in PPAR function. This point is of critical interest, as identi-
ﬁcation of the mechanism(s) of tubulin loss will serve as an
important step in identifying the therapeutic targets that are
exploited by T0070907, and in design of better ways to target
them. In HT-29 cells, α/β tubulin RNA levels were unaf-
fected, suggesting a post-transcriptional mechanism. Several
aspects of tubulin production could be involved, includ-
ing degradation, translation initiation, chaperone-mediated
folding/assembly of tubulin heterodimers (Figure 1), and
disruption of microtubule-associated protein interactions
with tubulin.
Because the protein half-life of tubulin is believed to
be long (∼50 hours) [56, 57], detectable loss of tubulin
within 6 hours suggests a mechanism involving increased
decay. Tubulin can be targeted for proteasomal degradation
by the tubulin cofactor-like protein El [58]a n dp r o b a b l y
by other regulatory factors. However, proteasome inhibitors
did not prevent T0070907-induced tubulin loss [26], sug-
gesting that ubiquitin-mediated proteasomal degradation is
not a major factor. Other degradation pathways must be
investigated, especially the aggresome pathway, which can
replace proteasomal degradation, resulting in autophagic
clearanceandlysosomaldegradation[59,60].Itisalsoworth
noting that the estimate of long tubulin half-lives is based on
measurement in only two cell types, and may not apply to
HT-29 cells.
T0070907-induced tubulin loss is unlikely to be the
result of acute increases in tubulin monomer protein. Many
eukaryotic cells respond to a sudden increase in unpoly-
merized tubulin by reducing synthesis of tubulin [61–65]
in a process termed autoregulatory control. This mechanism
is associated with large reductions in tubulin mRNA; later
work showed that polysomal mRNA in the process of being
translated was speciﬁcally susceptible to an increased mRNA
decay [66, 67]. T0070907 induces little diﬀerence in tubulin
mRNAconcentrationsasmeasuredbyreal-timePCR[26].In
addition, at least in in vitro polymerization assays, T0070907
did not inhibit polymerization or cause depolymerization,
althoughitisimportanttonotethatdepolymerizationmight
occur in the cell as a result of alterations in microtubule-
associated protein function. However, nocodazole, which at
high (10μM) doses increases the amount of soluble tubulin
by inhibiting bulk microtubule polymerization [53], did not
aﬀect the tubulin protein levels in HT-29 cells. This result
strongly suggests that tubulin in these particular cells is not
strongly subject to autoregulatory control. However, it is
formally possible that T0070907 might increase the soluble
tubulin pool far more strongly than nocodazole. Direct
measurement of the amount of tubulin in the polymerized
and free pools after T0070907 treatment should resolve these
questions.
There is also the potential for T0070907 to control
translation initiation or other aspects of protein synthesis.
The TZD PPARγ activators have been shown to suppress
translation initiation in a PPARγ-independent manner
through a mechanism involving intracellular Ca2+ store
depletion and subsequent inhibition of the eIF2 translation
inititationfactor[68].ItispossiblethatT0070907alsoaﬀects
some aspect(s) of the translation machinery.
The loss of tubulin and cell death phenotypes induced
by T0070907 can be mimicked by knockdown of chaperone
proteinsinvolvedinfoldingandassemblyoftubulin,suggest-
ing that PPARγ inhibitors may interfere with this pathway.
Tubulin production and assembly into α/β heterodimers
require the presence of multiple chaperone proteins, includ-
ing the multisubunit chaperones prefoldin [69] and CCT
[70], and tubulin cofactor proteins A–E [71]( Figure 1).
Additionalchaperonemodulatoryproteins,includingPhLP3
[72] and E-like (El) [58], also modulate the function of
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causes reduced tubulin levels [73], as does knockdown of
tubulin cofactor A [74]. It is possible that PPARγ inhibitors
bind directly to and inhibit some of the chaperone proteins.
Alternatively, they may change the expression or function of
any of the chaperone subunits or cofactors.
Knockdown of microtubule-associated proteins (MAPs)
can also cause loss of tubulin, and PPARγ inhibitors could
interfere with MAPs or dysregulate MAP expression. MAPs
are a functional class of proteins that physically interact
with microtubules or microtubule precursors and regulate
microtubule functions. Some MAPs directly control the rate
of association or dissociation of α/β tubulin heterodimers
with the ends of the microtubule, as well as the levels
of soluble tubulin in the cell, and thus aﬀect microtubule
dynamics (Figure 1). Others link microtubules to signal-
ing complexes and other cytoskeletal components [75].
Mutations in stathmin, a multifunctional MAP that both
destabilizes microtubules and sequesters α/β tubulin het-
erodimers so that they are not part of the freely polymerizing
pool, led to reduced α tubulin levels (β tubulin was not
checked) and fewer microtubules in Drosophila oocytes
[76]. In the same system, stathmin overexpression increased
tubulin levels. Knockdown of MAP4, generally thought
to be a microtubule-stabilizing MAP, also caused reduced
tubulin levels [77]. In both cases, it is possible, but has not
been shown directly, that these eﬀects were subsequent to
autoregulatory control.
7. ARE THE CELL DEATH AND TUBULIN EFFECTS OF
T0070907 OR GW9662 DEPENDENT UPON PPARγ?
It is important to establish whether the eﬀects of T0070907
and GW9662 on cell death can be separated from their
ability to target PPARγ. Although results in two cell lines
[23, 29] have shown that PPARγ knockdown causes cell
death or potentiates the eﬀects of the inhibitors, this result
does not occur in all cell lines [26]. In addition, the inhibitor
doses required for the cell death (3–50μM for T0070907
and 10–50μM for GW9662) in all cell lines tested are much
higher than those needed to inhibit the transcriptional eﬀect
of PPARγ by at least 90%, given an approximate eﬀective
dissociation constant in the low nanomolar range (Table 1).
This result suggests that at least some of the cell death eﬀects
are indeed independent of PPARγ.T h ed i ﬀerences in cell
lines may reﬂect a true disparity in the role of PPARγ in
maintaining cell growth and survival in diﬀerent cell types,
and suggests that the HT-29 system is ideal for examining
the PPARγ-independent eﬀects of T0070907.
TheeﬀectofT0070907 andGW9662 ontubulinhasbeen
examined primarily in HT-29 colon cancer cells, although
the loss of adhesion, cell rounding, and cell death occur
in multiple colorectal cancer cell lines ([26]a n dK L S ,
unpublished data). In HT-29 cells, the eﬀects on tubulin
are not replicated by PPARγ knockdown, or reductions in
the closely related PPARδ. However, given the fact that at
50μM T0070907, PPARγ,P P A R α and PPARδ transcriptional
activities are all expected to be at least partially repressed,
based on the predicted dissociation constants (Table 1), it is
possible that multiple PPAR molecules must be inactivated
in order to create the conditions necessary for tubulin
loss. In addition, it is entirely possible that a non-PPAR-
dependent event must occur in the context of knockdown
of one or more of the PPAR transcription factors. This idea
is somewhat contradicted by the observation that BADGE,
which does not strongly aﬀect PPARα/δ at 100μM[ 10], does
cause a reduction in the amount of tubulin [26]. However, in
this case, it is possible that the tubulin loss was a separate
phenomenon, secondary to extensive cell death. Further
experiments will be needed to address this issue.
8. ADVANTAGES AND DISADVANTAGES TO
USING PPARγ INHIBITORS AS
TUBULIN-TARGETING THERAPIES
To our knowledge, the PPARγ inhibitors are the ﬁrst
described instance of a possible small molecule cancer
therapeutic that reduces tubulin levels. This result sug-
gests the exciting possibility that tubulin levels can be
modulated therapeutically, in a tumor-speciﬁc manner, to
kill cancer cells. While the current microtubule-targeting
agents have signiﬁcant antitumor activity in many cancer
types, they are not eﬀective in all cancers, and acquired
resistance is a problem [78]. In addition, because these
drugs diﬀerentially targeting rapidly proliferating cells, they
cause leukopenia [78]. For the same reason, they are not
expected to target cancer stem cells, owing to their generally
slow proliferation rate [79]. Microtubule-targeting drugs
also induce peripheral neuropathy [80] and may interfere
with mental function [81], presumably as a result of their
eﬀects on neuronal microtubule function. T0070907 and/or
GW9662, or second-generation compounds, by virtue of
acting by a diﬀerent mechanism, might ameliorate some of
the diﬃculties of the standard MTAs.
Several questions must be addressed, when considering
these compounds, or others like them, as cancer therapies.
To date, preclinical data on the bioavailability of either
T0070907 or GW9662 has not been published, although a
pilot experiment with radiolabeled GW9662 indicates that
these compounds are delivered to tumors [82]. It is also
important to consider tumor speciﬁcity and whether the
tubulin-targeting eﬀect can be separated from the PPAR
inhibitory eﬀect.
Inherent or acquired resistance to current microtubule-
targeting agents is a serious problem in microtubule-based
cancer therapy. One major source of resistance is the expres-
sion of alternate tubulin isoforms with inherently diﬀerent
microtubule dynamics [83]. These diﬀerences antagonize
the eﬀects of the drug, and allow the cell to continue
proliferating. It appears that T0070907 causes concurrent
loss of multiple tubulin isoforms (KLS, unpublished data),
presumably by some regulatory mechanism common to all
isoforms. It is therefore reasonable to suspect that T0070907
would suppress levels of the tumor-speciﬁc alternate iso-
forms as well. The microtubule targeting drugs are also
generally good substrates for drug eﬄux pumps that prevent
accumulation of therapeutic levels of drug [78]. For this
reason, it would be useful to test whether T0070907 and
GW9662 are substrates for the common drug eﬄux pumps.6 PPAR Research
As tubulin is a constituent of all cells, the eﬀects of
T0070907 or similar compounds on normal cells is a serious
consideration. To date, these compounds have only been
tested in one mouse model of cancer. At oral doses that
reduced tumor growth (1–5mg/kg/d), the compounds did
not cause weight loss or malaise in mice [26]. In addition,
recent unpublished results from our laboratory showed that
10mg/kg/d orally, maintained daily for three weeks, did not
cause any alterations in values from a standard complete
blood count with diﬀerential. The reasons for this apparent
speciﬁcity will need to be examined in more detail, as well
as whether tubulin levels are reduced in normal and tumor
tissues in vivo. The fact that radioactively labeled GW9662
preferentially accumulated in tumor cells as compared to
many normal tissues in mice [82] suggests that part of
the speciﬁcity may simply reﬂect where the compound is
accumulating. Another possibility is that these compounds
do act through the tubulin chaperone system. Components
of this system are upregulated in some tumor cells [84–
86], and tumor cells may require higher levels of tubulin
chaperone function, as they do with the HSP90 chaperone
[87, 88]. If this were true, this might explain why tumor cells
are preferentially susceptible to the PPARγ inhibitors.
A major question is whether suppression of PPARγ (or
PPARα/δ) function is required for the tubulin-targeting
eﬀects of T0070907 and/or GW9662. If suppression of
PPARγ cannot be separated from the tubulin targeting
eﬀects, it will be necessary to carefully balance the therapeu-
tic eﬀects of PPARγ inhibitors on tubulin with the possible
deleterious eﬀects of PPARγ inhibition on physiologic pro-
cesses that aﬀect tumor growth. In addition to the question
of whether PPARγ is a tumor suppressor or has tumor-
promoting activity in each cancer cell type, the eﬀects of
PPARγ onangiogenesis[14,16]andtheimmunesystem[32]
must also be considered.
The role of PPARγ itself in angiogenesis, in contrast to
the eﬀects of TZD PPARγ activators, is still relatively unclear
[16]. TZDs can reduce the production of proangiogenic
FGF and VEGF factors, interfere with endothelial cell
migration, and inhibit vascular tube formation, as well as
reduce production of inﬂammatory mediators that stimulate
angiogenesis.However,todate,onlyCD36upregulation[89]
and decreased iNOS production [6] are known to be PPARγ-
dependent. It is also noteworthy that standard microtubule-
targeting agents in clinical use disrupt tumor-speciﬁc vascu-
lature [90, 91]. It will be interesting to determine whether
the PPARγ inhibitors also suppress tumor angiogenesis, and
whether the eﬀects are linked to PPARγ and/or tubulin.
In all probability, the net eﬀect of PPARγ inhibition
on the immune system will depend upon the individual
characteristics of the tumor, including the site of the tumor,
the role of PPARγ in tumor-intrinsic biology, and the pres-
e n c ea n dt y p eo fi m m u n ei n ﬁ l t r a t i o n .Av a r i e t yo fi m m u n e
cells inﬁltrate tumors, including macrophage lineage cells, T
lymphocytes, mast cells, and natural killer (NK) cells [92].
All of these cells have the potential to promote or hinder
tumor growth, depending on the cytokines they secrete and
the cell-mediated cytotoxic eﬀects they are able to promote.
Both macrophage and regulatory T cell (Treg) functions
are modulated by PPARγ.M o n o c y t e sc a nd i ﬀerentiate into
M1 or M2 macrophages in response to diﬀerent stimuli
[93, 94]. In general, M1 macrophages secrete large quantities
of inﬂammatory cytokines, have cytotoxic activity toward
tumor cells, elicit the adaptive immune response, and are
associated with a better tumor prognosis. In contrast, M2
macrophages secrete immunosuppressive cytokines, have
poor antigen-presenting capacity, and promote angiogenesis
and tissue remodeling; these macrophages are generally
associated with a poorer prognosis [93]. Since PPARγ acti-
vation of human monocytes promotes M2 polarization [95],
PPARγ inhibitors might be expected to favor production of
M1tumor-suppressinginﬂammatorymacrophages.Treg cells
lacking PPARγ are unable to suppress colitis in a regulatory
T cell-dependent model of inﬂammatory bowel disease [96],
arguing that PPARγ is required for suppressive regulatory
function. As Treg activity can impair tumor rejection [97],
PPARγ inhibitors should suppress Treg thereby aiding tumor
rejection.
9. CONCLUSIONS
The microtubule-targeting agents are one of the most
successful classes of cancer therapeutics, but ongoing issues
with resistance make the development of additional strate-
gies for targeting microtubules extremely desirable. The
recent discovery that the small molecule PPARγ inhibitor
compounds reduce tubulin protein levels, without aﬀecting
in vitropolymerization rates,suggeststheexciting possibility
that targeting tubulin levels directly, rather than micro-
tubule dynamics, might be an additional way to manipulate
microtubule biology to kill cancer cells. Several questions,
including whether inhibition of PPAR function is required
for the tubulin eﬀect, the nature of the tumor speciﬁcity,
the ultimate targets of these compounds, and whether better
compounds with similar tubulin targeting eﬀects can be
designed, must be answered before this strategy can be fully
realized.
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